Pharmaxis Announces SSAO/VAP-1 Inhibitor Ready for the Clinic
Release Date: 28/08/2014 12:00am
Pharmaceutical development company Pharmaxis today announced that it has completed preclinical development of its Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor (PXS4728A) and is ready to commence human clinical phase I studies in Q1 2015.
The SSAO/VAP-1 enzyme contributes to various forms of chronic inflammation in humans and is a marker for disease severity in conditions such as atherosclerosis, liver and kidney inflammation. Pharmaxis will focus the clinical development on inflammatory diseases with high unmet clinical need including Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Steatohepatitis (NASH).
Categories: News and Media